Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  5.50 9.91% 61.00 759,680 16:06:43
Bid Price Offer Price High Price Low Price Open Price
60.00 62.00 61.00 55.50 55.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.74 -2.24 -2.49 54
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:52 O 130,500 61.00 GBX

Optibiotix Health (OPTI) Latest News

More Optibiotix Health News
Optibiotix Health Investors    Optibiotix Health Takeover Rumours

Optibiotix Health (OPTI) Discussions and Chat

Optibiotix Health Forums and Chat

Date Time Title Posts
21/1/202106:33OptiBiotix - The uncensored thread 45,994
21/1/202106:09OptiBiotix Health PLC - 12,330
08/1/202115:16OptiBiotix Health (Facts NOT Fiction)5,365
08/1/202110:11OptiBiotix - Better Science, Better Health. Better buy some!57,605
15/11/202001:00OptiBiotix Health (Facts NOT Fiction)31

Add a New Thread

Optibiotix Health (OPTI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-20 17:08:5261.00130,50079,605.00O
2021-01-20 16:25:0960.13600360.75O
2021-01-20 16:22:2460.131,000601.25O
2021-01-20 16:19:0862.002414.88O
2021-01-20 16:17:4962.0084.96O
View all Optibiotix Health trades in real-time

Optibiotix Health (OPTI) Top Chat Posts

DateSubject
20/1/2021
08:20
Optibiotix Health Daily Update: Optibiotix Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 55.50p.
Optibiotix Health Plc has a 4 week average price of 49p and a 12 week average price of 46.50p.
The 1 year high share price is 72p while the 1 year low share price is currently 24p.
There are currently 87,940,601 shares in issue and the average daily traded volume is 497,145 shares. The market capitalisation of Optibiotix Health Plc is £53,643,766.61.
19/1/2021
07:33
manc10: OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the appointment of Dr Taru Jain as Business Development Director in Asia and Christopher Nother, as the pharmaceutical lead on LPLDL®. Christopher Nother is joining OptiBiotix on a part time consultancy basis to support the growth of LPLDL® in pharma, either as an 'over the counter' (OTC) product used by itself or in combination with existing treatments (e.g. statins), or a drug biotherapeutic in markets outside the USA. Chris joins OptiBiotix after leading global business development at Nypro Healthcare's (now Jabil Healthcare) Pharmaceutical Delivery Systems division. Jabil Healthcare describes itself as the world's leading healthcare contract manufacturing organisation on its website, and its parent company, Jabil Inc., is a Fortune 200 world leading manufacturing solutions provider. Chris advises a number of other businesses in the healthcare and drug delivery systems sectors and is Interim CEO at Surgical Synergy Limited. Dr Taru Jain will join OptiBiotix's management team in March 2021 to focus on business development and growing sales in the strategically important Indian and Asian markets. Dr. Taru was previously the Executive Director at Akums Drugs & Pharmaceuticals Ltd, (Akums website states it is India's single largest Contract Research and Manufacturing (CRAMS) organisation responsible for manufacturing approximately 11-12% of all drugs consumed in the country). Her responsibilities at Akums included in-licensing worldwide, marketing strategy and design, client and account relationship management, along with representation of the company on national and international forums. She has over 10 years of experience across the Indian healthcare value chain as well as primary knowledge of the demand pattern of the prescription and OTC market. Stephen OHara CEO of OptiBiotix Health plc commented: "OptiBiotix made strong progress last year in growing sales and reducing costs and enters 2021 with a strong balance sheet and lead pipeline. The Company is now focused on the next stage of its development: growing sales and profitability in its divisions, and commercialising its next generation products (e.g. microbiome modulators, SweetBiotix, and drug biotherapeutics). "We now have more opportunities across a broader range of areas that can effectively be commercialised with the size of the current team. Chris and Taru bring additional capacity, expertise and a network of contacts in product areas and markets of strategic interest which will support future revenue growth. These appointments are consistent with our strategy of developing multiple revenue streams from both consumer and pharmaceutical products across all OptiBiotix technology platforms."
18/1/2021
11:31
sentiment riles: All joking aside, opti has been an easy range to play , and the march drop was only going to return to 2 year fwd share price anyway Its been dancing bewtween 2YF to zero'd EPS forever [...] — City Trading & Investing (@city_trd_invt) January 18, 2021
11/1/2021
20:21
sentiment riles: Dont know why you bother manc. Unless all you need is a few retail investors to churn opti price at right time for 'others'? Its advfn. A forum about a little known stock, one of so many thousands, failing to make money for years I do get it You lot must be heavy involved, when such a little unknown, requires 24/7 'crew monitoring' for years Ultimately though, it will only take one respected fund to look at it, rate it, and thats end of that Some 5 min read article by 'those respected' Hope that doesnt happen Going to blow away years of Slarty n manc show looooooooooooooool Seriously now, who can really look at this thread etc, and not believe, on the take hahaha
10/1/2021
15:03
manc10: manc1010 Jan '21 - 11:01 - 44743 of 44846 Edit 0 0 0 ts the ''barking mad'' blogger again, back as the chief ramper role, specifically regarding OptiBiotix Health PLC (OPTI). Stephen O'Hara called me on 6th January for no other reason than to catch up and see how I am health-wise; I nice warm gesture during a hectic time for him and his small team. It may seem the company is not busy because the perception limited RNS's over the holiday period and the whole of December have been thin on the ground. The company is busy preparing the accounts, chasing the last remaining shekels in preparation for the FY 2020 accounts. I took the opportunity to ask about the anticipated launch of Holland & Barrett's new branded weight management products to be launched under the new brand. SlimExpert. Stephen would not confirm the launch schedule but did say there is no issue, all is going according to plan. As you can see from the link, this appears to be a significant increase in SKU's from 3 to 8, clear evidence Holland & Barratt are cleared with SlimBiome. I should mention at this point, the SlimBiome brand was merely on loan for 12 months because Holland & Barratt had no in-house brand of their own. For the bears to argue SlimBiome is a failure cannot be the case, otherwise, advance from 3 to 8 SKU's? Utter madness! I know most of us are eager for what we hope will be a dual NASDAQ listing this year. It is only my view that Stephen has not indicated to me when he plans to list, but he said the accounts will need to be audited for both IFR15 & GAPP, the latter USA filings. This suggests that we could see movement before the full year accounts statutory filings by the end of June. It could be a dry run for the accountants, meaning I am getting ahead of myself; we shall see in due course. We know there will be further strengthening the board, which involves at least two additions. Obviously, these will need to be in place ahead of any new listing. Plus there is ongoing work to further cement the value of IP with more clinical data, which also protects the IP. It is often ignored or unknown how significant OptiBiotix's net value of SkinBioTherapeutics (SBTX) is seemingly hidden by the bears and detractors when they argue OptiBiotix is overvalued, which is a rank stupid conclusion. For example; Stephen recognised the significant value is SkinBiotix; hence his investment's of £250K (plus approximately £500K in building team) has led to an asset value of (25x 46m) = £11.5m, which will continue to rise as Stuart Ashman and his team of leaders, POC for skin health from corporates around the world. manc1010 Jan '21 - 11:03 - 44744 of 44846 Edit 0 0 0 Its the ''barking mad'' blogger again, back as the chief ramper role, specifically regarding OptiBiotix Health PLC (OPTI). Stephen O'Hara called me on 6th January for no other reason than to catch up and see how I am health-wise; I nice warm gesture during a hectic time for him and his small team. It may seem the company is not busy because the perception limited RNS's over the holiday period and the whole of December have been thin on the ground. The company is busy preparing the accounts, chasing the last remaining shekels in preparation for the FY 2020 accounts. I took the opportunity to ask about the anticipated launch of Holland & Barrett's new branded weight management products to be launched under the new brand. SlimExpert. Stephen would not confirm the launch schedule but did say there is no issue, all is going according to plan. As you can see from the link, this appears to be a significant increase in SKU's from 3 to 8, clear evidence Holland & Barratt are cleared with SlimBiome. I should mention at this point, the SlimBiome brand was merely on loan for 12 months because Holland & Barratt had no in-house brand of their own. For the bears to argue SlimBiome is a failure cannot be the case, otherwise, advance from 3 to 8 SKU's? Utter madness! I know most of us are eager for what we hope will be a dual NASDAQ listing this year. It is only my view that Stephen has not indicated to me when he plans to list, but he said the accounts will need to be audited for both IFR15 & GAPP, the latter USA filings. This suggests that we could see movement before the full year accounts statutory filings by the end of June. It could be a dry run for the accountants, meaning I am getting ahead of myself; we shall see in due course. We know there will be further strengthening the board, which involves at least two additions. Obviously, these will need to be in place ahead of any new listing. Plus there is ongoing work to further cement the value of IP with more clinical data, which also protects the IP. It is often ignored or unknown how significant OptiBiotix's net value of SkinBioTherapeutics (SBTX) is seemingly hidden by the bears and detractors when they argue OptiBiotix is overvalued, which is a rank stupid conclusion. For example; Stephen recognised the significant value is SkinBiotix; hence his investment's of £250K (plus approximately £500K in building team) has led to an asset value of (25x 46m) = £11.5m, which will continue to rise as Stuart Ashman and his team of leaders, POC for skin health from corporates around the world.
10/1/2021
12:22
manc10: Life sciences business OptiBiotix Health plc (LON:OPTI) told shareholders it is now able to make dividend payments in future, should it want to. The cancellation of its share premium account has been ratified, creating reserves that are available for distribution to shareholders. "I am pleased to report that both shareholders and the courts have confirmed the capital reduction. This allows OptiBiotix to make future dividend or 'dividend in specie' distributions to the company's shareholders should it be appropriate to do so. This is part of OptiBiotix's strategy of building value across its divisions and where possible releasing value back to shareholders," said Stephen O'Hara, the chief executive officer of OptiBiotix.
10/1/2021
12:05
manc10: on 4d no comparison opti have not raised 100s of million and the share price has not come down from 10 quid to 1 quid and opti divisions will be profitable by year end 2020
10/1/2021
11:03
manc10: Its the ''barking mad'' blogger again, back as the chief ramper role, specifically regarding OptiBiotix Health PLC (OPTI). Stephen O'Hara called me on 6th January for no other reason than to catch up and see how I am health-wise; I nice warm gesture during a hectic time for him and his small team. It may seem the company is not busy because the perception limited RNS's over the holiday period and the whole of December have been thin on the ground. The company is busy preparing the accounts, chasing the last remaining shekels in preparation for the FY 2020 accounts. I took the opportunity to ask about the anticipated launch of Holland & Barrett's new branded weight management products to be launched under the new brand. SlimExpert. Stephen would not confirm the launch schedule but did say there is no issue, all is going according to plan. As you can see from the link, this appears to be a significant increase in SKU's from 3 to 8, clear evidence Holland & Barratt are cleared with SlimBiome. I should mention at this point, the SlimBiome brand was merely on loan for 12 months because Holland & Barratt had no in-house brand of their own. For the bears to argue SlimBiome is a failure cannot be the case, otherwise, advance from 3 to 8 SKU's? Utter madness! I know most of us are eager for what we hope will be a dual NASDAQ listing this year. It is only my view that Stephen has not indicated to me when he plans to list, but he said the accounts will need to be audited for both IFR15 & GAPP, the latter USA filings. This suggests that we could see movement before the full year accounts statutory filings by the end of June. It could be a dry run for the accountants, meaning I am getting ahead of myself; we shall see in due course. We know there will be further strengthening the board, which involves at least two additions. Obviously, these will need to be in place ahead of any new listing. Plus there is ongoing work to further cement the value of IP with more clinical data, which also protects the IP. It is often ignored or unknown how significant OptiBiotix's net value of SkinBioTherapeutics (SBTX) is seemingly hidden by the bears and detractors when they argue OptiBiotix is overvalued, which is a rank stupid conclusion. For example; Stephen recognised the significant value is SkinBiotix; hence his investment's of £250K (plus approximately £500K in building team) has led to an asset value of (25x 46m) = £11.5m, which will continue to rise as Stuart Ashman and his team of leaders, POC for skin health from corporates around the world.
10/1/2021
11:01
manc10: ts the ''barking mad'' blogger again, back as the chief ramper role, specifically regarding OptiBiotix Health PLC (OPTI). Stephen O'Hara called me on 6th January for no other reason than to catch up and see how I am health-wise; I nice warm gesture during a hectic time for him and his small team. It may seem the company is not busy because the perception limited RNS's over the holiday period and the whole of December have been thin on the ground. The company is busy preparing the accounts, chasing the last remaining shekels in preparation for the FY 2020 accounts. I took the opportunity to ask about the anticipated launch of Holland & Barrett's new branded weight management products to be launched under the new brand. SlimExpert. Stephen would not confirm the launch schedule but did say there is no issue, all is going according to plan. As you can see from the link, this appears to be a significant increase in SKU's from 3 to 8, clear evidence Holland & Barratt are cleared with SlimBiome. I should mention at this point, the SlimBiome brand was merely on loan for 12 months because Holland & Barratt had no in-house brand of their own. For the bears to argue SlimBiome is a failure cannot be the case, otherwise, advance from 3 to 8 SKU's? Utter madness! I know most of us are eager for what we hope will be a dual NASDAQ listing this year. It is only my view that Stephen has not indicated to me when he plans to list, but he said the accounts will need to be audited for both IFR15 & GAPP, the latter USA filings. This suggests that we could see movement before the full year accounts statutory filings by the end of June. It could be a dry run for the accountants, meaning I am getting ahead of myself; we shall see in due course. We know there will be further strengthening the board, which involves at least two additions. Obviously, these will need to be in place ahead of any new listing. Plus there is ongoing work to further cement the value of IP with more clinical data, which also protects the IP. It is often ignored or unknown how significant OptiBiotix's net value of SkinBioTherapeutics (SBTX) is seemingly hidden by the bears and detractors when they argue OptiBiotix is overvalued, which is a rank stupid conclusion. For example; Stephen recognised the significant value is SkinBiotix; hence his investment's of £250K (plus approximately £500K in building team) has led to an asset value of (25x 46m) = £11.5m, which will continue to rise as Stuart Ashman and his team of leaders, POC for skin health from corporates around the world.
09/1/2021
19:19
manc10: ProBiotix Health, a fully-owned subsidiary of OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, communicate that ALFASIGMA S.p.A. ("ALFASIGMA") has recently announced the launch of a food supplement containing the cholesterol reducing LPLDL® probiotic strain developed by ProBiotix Health. ALFASIGMA will market this first of its kind nutraceutical probiotic in Italy for cholesterol reduction. This agreement follows on from the announcement (RNS: 21 June 2018) that OptiBiotix had entered into license agreement with "ALFASIGMA" to exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in Italy. ALFASIGMA, is a multinational pharmaceutical company with 2018 revenues in excess of €1 billion and around 3000 employees globally. Whilst Italy is its core market, ALFASIGMA is present in more than 90 countries through distributors and subsidiaries. The launch is being supported by an extensive marketing campaign aimed at General Practitioners, cardiologist, and pharmacists, to promote treatment of at risk patients using a natural, scientifically formulated, food supplement. Italy is the largest probiotic supplement market in Europe, and the second largest market in the world, with an estimated >$500 million probiotic supplements market, and a 25% per annum growth forecast to 2021*.
07/1/2021
16:35
manc10: OptiBiotix - The uncensored thread - Post 44377OPTI Optibiotix Health Plc kreature 07 Jan 2021 15:07 kreature Gone short on the Opti just now manc because, well needs no explaining really loooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooool
Optibiotix Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OPTI
Optibiotix..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210121 06:33:20